Redmile Group LLC cut its stake in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) by 0.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,734,044 shares of the biotechnology company’s stock after selling 74 shares during the quarter. Atara Biotherapeutics makes up 2.3% of Redmile Group LLC’s portfolio, making the stock its 12th biggest holding. Redmile Group LLC owned 8.95% of Atara Biotherapeutics worth $38,277,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently bought and sold shares of ATRA. Eagle Asset Management Inc. increased its stake in shares of Atara Biotherapeutics by 17.8% in the second quarter. Eagle Asset Management Inc. now owns 1,492,976 shares of the biotechnology company’s stock worth $20,901,000 after acquiring an additional 225,367 shares during the last quarter. EcoR1 Capital LLC increased its stake in shares of Atara Biotherapeutics by 101.5% in the first quarter. EcoR1 Capital LLC now owns 434,812 shares of the biotechnology company’s stock worth $8,935,000 after acquiring an additional 219,000 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Atara Biotherapeutics by 617.9% in the first quarter. Goldman Sachs Group Inc. now owns 201,214 shares of the biotechnology company’s stock worth $4,135,000 after acquiring an additional 173,184 shares during the last quarter. Neuberger Berman Group LLC increased its stake in shares of Atara Biotherapeutics by 15.7% in the second quarter. Neuberger Berman Group LLC now owns 967,980 shares of the biotechnology company’s stock worth $13,552,000 after acquiring an additional 131,465 shares during the last quarter. Finally, Camber Capital Management LLC acquired a new position in shares of Atara Biotherapeutics in the first quarter worth $2,569,000. 82.95% of the stock is currently owned by institutional investors and hedge funds.

Several equities analysts have commented on the stock. Jefferies Group LLC reissued a “buy” rating and set a $30.00 target price on shares of Atara Biotherapeutics in a research report on Thursday. Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and set a $20.00 target price on shares of Atara Biotherapeutics in a research report on Friday. Canaccord Genuity set a $47.00 target price on shares of Atara Biotherapeutics and gave the stock a “buy” rating in a research report on Monday, August 7th. ValuEngine raised shares of Atara Biotherapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Finally, Zacks Investment Research downgraded shares of Atara Biotherapeutics from a “buy” rating to a “hold” rating in a research report on Monday, August 28th. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company. Atara Biotherapeutics has a consensus rating of “Hold” and an average price target of $24.40.

COPYRIGHT VIOLATION WARNING: This news story was first published by Watch List News and is owned by of Watch List News. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be accessed at https://www.watchlistnews.com/redmile-group-llc-reduces-stake-in-atara-biotherapeutics-inc-atra/1617935.html.

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) traded down 4.42% during trading on Friday, reaching $16.20. 198,994 shares of the company’s stock traded hands. The firm’s market cap is $495.06 million. The firm has a 50 day moving average price of $15.35 and a 200-day moving average price of $15.62. Atara Biotherapeutics, Inc. has a 12 month low of $11.80 and a 12 month high of $23.00.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.94) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.89) by ($0.05). On average, analysts forecast that Atara Biotherapeutics, Inc. will post ($3.89) earnings per share for the current fiscal year.

In related news, CEO Isaac E. Ciechanover sold 2,800 shares of the company’s stock in a transaction dated Monday, July 24th. The shares were sold at an average price of $16.94, for a total value of $47,432.00. Following the transaction, the chief executive officer now owns 731,859 shares in the company, valued at approximately $12,397,691.46. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Christopher Haqq sold 6,000 shares of the company’s stock in a transaction dated Monday, July 17th. The shares were sold at an average price of $14.92, for a total transaction of $89,520.00. Following the completion of the transaction, the executive vice president now owns 362,080 shares in the company, valued at approximately $5,402,233.60. The disclosure for this sale can be found here. In the last quarter, insiders sold 53,909 shares of company stock worth $810,518. 16.20% of the stock is owned by company insiders.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Want to see what other hedge funds are holding ATRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Atara Biotherapeutics, Inc. (NASDAQ:ATRA).

Institutional Ownership by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.